Loading...

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review

BACKGROUND: Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor that along with two nucleoside reverse transcriptase inhibitors is one of several regimens recommended by the United States, United Kingdom and European Union for first-line antiretroviral treatment of peo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Rutherford, George W., Horvath, Hacsi
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5063380/
https://ncbi.nlm.nih.gov/pubmed/27736859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0162775
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!